CN: 32-1845/R
ISSN: 2095-6975
Cite this paper:
0
LIU Zhen-Zhen, WENG Hong-Bo, ZHANG Li-Jie, PAN Ling-Yu, SUN Wei, CHEN Hai-Xia, CHEN Mei-Yu, ZENG Tao, ZHANG Yun-Yi, CHEN Dao-Feng, LI Hong. Bupleurum polysaccharides ameliorated renal injury in diabetic mice associated with suppression of HMGB1-TLR4 signaling[J]. Chinese Journal of Natural Medicines, 2019, 17(9): 641-649

Bupleurum polysaccharides ameliorated renal injury in diabetic mice associated with suppression of HMGB1-TLR4 signaling

LIU Zhen-Zhen1, WENG Hong-Bo1, ZHANG Li-Jie1, PAN Ling-Yu1, SUN Wei1, CHEN Hai-Xia1, CHEN Mei-Yu1, ZENG Tao3, ZHANG Yun-Yi1, CHEN Dao-Feng2, LI Hong1
1 Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai 201203, China;
2 Department of Pharmacognosy, School of Pharmacy, Fudan University, Shanghai 201203, China;
3 Clinical trial institution, Obstetrics and Gynecology Hospital of Fudan University, Shanghai 201203, China
Abstract:
Bupleurum polysaccharides (BPs) is isolated from Bupleurum smithii var. parvifolium, a key traditional Chinese medicine. The study was to investigate the effects of BPs on diabetic kidney injury. After two intraperitoneal injections of streptozotozin (STZ) 100 mg·kg-1, renal injury in diabetic mice was induced and BPs was orally administrated at dosages of 30 and 60 mg·kg-1·d-1. The STZ injected mice developed renal function damage, renal inflammation and fibrosis known as diabetic kidney disease (DKD). BPs significantly reduced serum creatinine level and urinary albumin excretion rate, with the attenuated swelling of kidneys. BPs treatment obviously alleviated the pathological damage of renal tissue. The progression of renal injury in BPs treated mice was inhibited with less expression of type IV collagen (Col IV), fibronectin (FN) and α-smooth muscle actin (α-SMA). The inhibition of inflammation in kidney was associated with the reduced level of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). BPs administration suppressed the over-expression of toll like receptor 4 (TLR4) and high-mobility group box 1 (HMGB1) with lowered activity of nuclear factor kappa B (NF-κB) in renal tissue of diabetic mice. Oral administration of BPs effectively prevented the development of renal injury in diabetic mice. This study suggested that the protection provided by BPs might affect through the interruption of HMGB1-TLR4 pathway, leading to the inhibition of renal inflammation and fibrotic process.
Key words:    Renal injury    Bupleurum    High-mobility group box    Toll-like receptor 4    Inflammation    Renal fibrosis    Polysaccharides   
Received: 2019-01-14   Revised:
Tools
PDF (12929 KB) Free
Print this page
Email this article to others
Authors
Articles by LIU Zhen-Zhen
Articles by WENG Hong-Bo
Articles by ZHANG Li-Jie
Articles by PAN Ling-Yu
Articles by SUN Wei
Articles by CHEN Hai-Xia
Articles by CHEN Mei-Yu
Articles by ZENG Tao
Articles by ZHANG Yun-Yi
Articles by CHEN Dao-Feng
Articles by LI Hong
References:
[1] Murphy D, McCulloch CE, Lin F, et al. Trends in prevalence of chronic kidney disease in the United States[J]. Ann Intern Med, 2016, 165(7):473-481.
[2] Usha P, Carol P. The role of toll-like receptors in diabetic kidney disease[J]. Curr Opin Nephrol Hypertens, 2018, 27(1):30-34.
[3] Tesch GH. Diabetic nephropathy-is this an immune dis-order?[J]. Clin Sci, 2017, 131(16):2183-2199.
[4] Anders HJ. Signaling danger:Toll-like receptors and their potential roles in kidney disease[J]. J Am Soc Nephrol, 2004, 15(4):854-867.
[5] Ma J, Chadban SJ, Zhao CY, et al. TLR4 activation promotes podocyte injury and interstitial fibrosis in diabetic nephropathy[J]. PLoS One, 2014, 9(5):e97985.
[6] Wang Y, Zhong J, Zhang X, et al. The role of HMGB1 in the pathogenesis of type 2 diabetes[J]. J Diabetes Res, 2016, 2016:1-11.
[7] Cheng X, Li H, Yue X, et al. Macrophage immunomodulatory activity of the polysaccharides from the roots of Bupleurum smithii var. parvifolium[J]. J Ethnopharmacol, 2010, 130(2):363-368.
[8] Xu H, Zhang Y, Zhang J, et al. Isolation and characterization of an anti-complementary polysaccharide D3-S1 from the roots of Bupleurum smithii[J]. Int Immunopharmacol, 2007, 7(2):175-182.
[9] Pan L, Weng H, Li H, et al. Therapeutic effects of Bupleurum polysaccharides in Streptozotocin induced diabetic mice[J]. PLoS One, 2015, 10(7):e0133212.
[10] Cheng XQ, Song LJ, Li H, et al. Beneficial effect of the polysaccharides from Bupleurum smithii var. parvifolium on "two-hit" acute lung injury in rats[J]. Inflammation, 2012, 35(5):1715-22.
[11] Jiang Y, Li H, Zhang Y, et al. Beneficial effect of Bupleurum polysaccharides on autoimmune-prone MRL-lpr Mice[J]. Clin Dev Immunol, 2012, 2012:1-11.
[12] Wu J, Zhang YY, Guo L, et al. Bupleurum polysaccharides attenuates lipopolysaccharide-induced inflammation via modulating Toll-like receptor 4 signaling[J]. PLoS One, 2013, 8(10):e78051.
[13] Wang Z, Li H, Xu H, et al. Beneficial effect of Bupleurum polysaccharides on autoimmune disease induced by Campylobacter jejuni in BALB/c mice[J]. J Ethnopharmacol, 2009, 124(3):481-487.
[14] Chiou WF, Tsai HR, Yang LM, et al. C5a differentially stimulates the ERK1/2 and p38 MAPK phosphorylation through independent signaling pathways to induced chemotactic migration in RAW264.7 macrophages[J]. Int Immunopharmacol, 2004, 4(10-11):1329-1341.
[15] Weng H, Han W, Xiong Y, et al. Taxus chinensis ameliorates diabetic nephropathy through down-regulating TGF-β1/Smad pathway[J]. Chin J Nat Med, 2018, 16(2):90-96.
[16] El Ghoul B, Daaboul Y, Korjian S, et al. Etiology of end-stage renal disease and arterial stiffness among hemodialysis patients[J]. Biomed Res Int, 2017, 2017:1-6.
[17] Mirijello A, Viazzi F, Fioretto P, et al. Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes[J]. BMC Nephrol, 2018, 19:347.
[18] Monteiro MB, Thieme K, Santos-Bezerra DP, et al. Be-ta-2-microglobulin (B2M) expression in the urinary sedi-ment correlates with clinical markers of kidney disease in patients with type 1 diabetes[J]. Metabolism, 2016, 6:816-824.
[19] Ponchiardi C, Mauer M, Najafian B. Temporal profile of diabetic nephropathy pathologic changes[J]. Curr Diabetes Rep, 2013, 13(4):592-599.
[20] Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis[J]. J Am Soc Nephrol, 2010, 21:1819-1834.
[21] Brosius FC. New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy[J]. Rev Endocr Metab Dis, 2008, 9(4):245-254.
[22] Chen F, Zhu X, Sun Z, et al. Astilbin inhibits high glu-cose-induced inflammation and extracellular matrix accumulation by suppressing the TLR4/MyD88/NF-κB pathway in rat glomerular mesangial cells[J]. Front Pharmacol, 2018, 9:1187.
[23] Awad AS, You H, Gao T, et al. Macrophage-derived tumor necrosis factor-α mediates diabetic renal injury[J]. Kidney Int, 2015, 88(4):722-733.
[24] Feigerlová E, Battaglia-Hsu S. IL-6 signaling in diabetic nephropathy:From pathophysiology to therapeutic perspectives[J]. Cytokine Growth F R, 2017, 37:57-65.
[25] SHI H, CHE Y, BAI L, et al. High mobility group box 1 in diabetic nephropathy (Review)[J]. Exp Ther Med, 2017, 14:2431-2433.
[26] Shi H, Kokoeva MV, Inouye K, et al. TLR4 links innate immunity and fatty acid-induced insulin resistance[J]. J Clin Invest, 2006, 116(11):3015-3025.
[27] Kim J, Sohn E, Kim C, et al. The role of high-mobility group Box-1 protein in the development of diabetic nephropathy[J]. Am J Nephrol, 2011, 33(6):524-529.
[28] Shi G, Shi G, Zhou J, et al. Involvement of growth factors in diabetes mellitus and its complications:A general review[J]. Biomed Pharmacother, 2018, 101:510-527.
[29] Yu M, Wang H, Ding A, et al. HMGB1 signals through toll- like receptor (TLR) 4 and TLR2[J]. Shock, 2006, 26(2):174-179.
[30] Chen X, Ma J, Kwan T, et al. Blockade of HMGB1 attenuates diabetic nephropathy in mice[J]. Sci Rep, 2018, 8(1):8319.
[31] Hussein MMA, Mahfouz MK. Effect of resveratrol and rosuvastatin on experimental diabetic nephropathy in rats[J]. Biomed Pharmacother, 2016, 82:685-692.